Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylnaltrexone for Opioid-induced Constipation in Advanced Illness
NCT02574819Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced constipation (OIC) comparing Methylnaltrexone with Placebo (2 arms). Primary endpoint: The proportion of subjects who had the Rescue-free laxation response within 4 hours of the initial dose. Status: unknown.
02
Drugs
methylnaltrexone
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT02574819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574819.